JOURNAL OF CLINICAL SURGERY ›› 2022, Vol. 30 ›› Issue (2): 142-144.doi: 10.3969/j.issn.1005-6483.2022.02.013

Previous Articles     Next Articles

Study on serum HIF-1 α and IL-6 expression in predicting the recurrence of elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery

  

  1. Department of Emergency,the 971th Hospital of the Chinese People's Liberation Army Navy,Shandong,Qingdao 266071, China
  • Received:2021-05-07 Accepted:2021-05-07 Online:2022-02-20 Published:2022-02-20

Abstract: Objective To observe the value of serum hypoxia inducible factor-1 α(HIF-1 α) and interleukin-6(IL-6) in predicting the recurrence of elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery. Methods 95 elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery treated in our hospital from January 2015 to December 2017 were selected,all patients received surgical treatment in our hospital and received the results of 3 months of follow-up,the recurrence of patients was observed;the serum HIF-1 α and IL-6 levels were detected at admission,the value of the two in predicting the recurrence of elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery was analyzed. Results Of 95 cases of elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery through follow-up evaluation,18 cases had recurrence,the recurrence rate was 18.95%;the proportion of tumor invasion of patients in the recurrence group was higher than that in the non occurrence group,and the serum HIF-1 α and IL-6 levels were higher than those in the non occurrence group at admission(P<0.05);ROC curve was drawn,the results showed that the AUC of serum HIF-1 α and IL-6 alone or combined to predict the risk of recurrence in patients with pituitary adenoma surgery were all >0.80,which had certain predictive value.Conclusion  The overexpression of HIF-1 α and IL-6 at admission may be associated with recurrence in elderly patients with pituitary adenomas after the treatment of transsphenoidal surgery,which had certain value in predicting the risk of recurrence in patients.

Key words: pituitary adenomas, transsphenoidal surgery, hypoxia inducible factor-1 α, interleukin-6;recurrence

[1] ZHENG Lili, SUN Qingfang, BIAN Liuguan.. Analysis of quality of life and impact factors in patients with non-functioning pituitary adenoma after transsphenoidal surgery [J]. JOURNAL OF CLINICAL SURGERY, 2019, 27(10): 850-852.
[2] HAN Yanlong, ZHANG Cheng, CHEN Dongming, et al.. Endoscopic surgical treatment of 52 cases of prolactinoma [J]. JOURNAL OF CLINICAL SURGERY, 2018, 26(11): 831-834.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] SHEN Xuhui, ZOU Jianjun. Clinical effect analysis of endovascular treatment of vertebral dissecting aneurysms[J]. JOURNAL OF CLINICAL SURGERY, 2018, 26(11): 825 -827 .
[2] . Experience in diagnosis and treatment of cryptogenic multifocal ulcerous stenosing enteritis[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(2): 144 -147 .
[3] FENG Qingyang, XU Jianmin. Interpretation of Chinese Expert Consensus on Robotic Surgery for Colorectal Cancer (2020 Edition)[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(5): 405 -408 .
[4] TAN Ling, LIU Zilin, MA Zhou, et al.. Nomogram of 5-year mortality risk prediction model in young-onset rectal cancer patients[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(5): 449 -453 .
[5] . Study on the relationship between the expression of hypoxia inducible factors and clinical features and prognosis in patients with gastric cancer in plateau area[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(6): 549 -553 .
[6] LIU Jianhua. Prevention and management of severe complications during and after minimally invasive pancreatic surgery[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(7): 613 -615 .
[7] ZHOU Lei, DING Shengyi, WANG Zhao, et al.. Analysis of deep lymph node metastasis of right recurrent laryngeal nerve in patients with papillary thyroid carcinoma undergoing total thyroidectomy[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(7): 652 -655 .
[8] . The “best” surgery for middle and lower thoracic esophageal squamous cell carcinoma[J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 781 -783 .
[9] . [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(9): 801 .
[10] . [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(9): 846 -847 .